Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biodesix Inc
(NQ:
BDSX
)
1.960
+0.110 (+5.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biodesix Inc
< Previous
1
2
3
4
Next >
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
May 31, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
May 25, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
May 24, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
May 18, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces First Quarter 2023 Results and Highlights
May 11, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
April 27, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
March 06, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
December 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
December 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
December 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
November 21, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
November 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Proposed Public Offering of Common Stock
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Third Quarter 2022 Results and Highlights
November 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
October 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
October 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Preliminary Revenue for Third Quarter 2022
October 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 06, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Named a Top 100 Healthcare Technology Company of 2022
August 09, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Second Quarter 2022 Results and Highlights
August 04, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
July 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
July 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
June 07, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Research Agreement with Top US Cancer Center
June 03, 2022
From
Biodesix, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.